| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 357 | 324 | 354 | 326 | 372 | 347 | 362 | 357 | 356 | 382 | 404 | 417 | 517 | 483 | 598 | 640 | 634 | 623 | 708 | 708 | 682 | 741 | 861 | 861 | 803 | 858 | 893 | 1,002 | 1,034 | 1,024 | 1,156 | 1,147 | 1,199 | 984 | 1,190 | 1,150 | 1,171 | 1,171 | 960 | 1,139 |
| Expenses | 306 | 260 | 284 | 260 | 292 | 275 | 284 | 277 | 278 | 302 | 316 | 337 | 460 | 381 | 480 | 519 | 516 | 477 | 556 | 573 | 500 | 552 | 602 | 633 | 597 | 648 | 737 | 823 | 837 | 808 | 908 | 915 | 967 | 849 | 977 | 905 | 920 | 921 | 763 | 907 |
| EBITDA | 51 | 64 | 69 | 67 | 81 | 72 | 78 | 81 | 79 | 80 | 89 | 80 | 57 | 102 | 118 | 121 | 119 | 146 | 152 | 135 | 182 | 189 | 260 | 228 | 205 | 209 | 156 | 179 | 197 | 216 | 248 | 232 | 232 | 135 | 213 | 245 | 251 | 251 | 197 | 232 |
| Operating Profit % | 14 % | 19 % | 19 % | 20 % | 21 % | 20 % | 21 % | 22 % | 22 % | 20 % | 20 % | 18 % | 9 % | 16 % | 17 % | 18 % | 16 % | 20 % | 21 % | 19 % | 17 % | 25 % | 30 % | 25 % | 25 % | 24 % | 17 % | 17 % | 19 % | 21 % | 21 % | 20 % | 19 % | 14 % | 18 % | 21 % | 21 % | 21 % | 20 % | 20 % |
| Depreciation | 14 | 14 | 14 | 15 | 15 | 16 | 19 | 19 | 18 | 18 | 19 | 20 | 20 | 25 | 27 | 27 | 27 | 29 | 30 | 39 | 39 | 34 | 36 | 37 | 45 | 39 | 40 | 39 | 40 | 43 | 44 | 48 | 49 | 49 | 53 | 52 | 53 | 53 | 53 | 57 |
| Interest | 8 | 8 | 9 | 10 | 9 | 8 | 8 | 8 | 8 | 8 | 10 | 8 | 6 | 7 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 6 | 5 | 6 | 7 | 13 | 17 | 19 | 23 | 26 | 29 | 29 | 27 | 26 | 27 |
| Profit Before Tax | 29 | 42 | 46 | 42 | 56 | 47 | 51 | 54 | 53 | 55 | 60 | 52 | 30 | 71 | 84 | 87 | 84 | 110 | 115 | 89 | 137 | 149 | 217 | 184 | 154 | 163 | 110 | 135 | 150 | 166 | 190 | 167 | 164 | 66 | 136 | 170 | 176 | 181 | 128 | 153 |
| Tax | 7 | 14 | 14 | 13 | 23 | 8 | 11 | 15 | 7 | 18 | 19 | 17 | 10 | 19 | 23 | 27 | 20 | 27 | 19 | 25 | 44 | 38 | 54 | 37 | 26 | 43 | 30 | 34 | 39 | 38 | 45 | 43 | 44 | 18 | 34 | 45 | 46 | 47 | 31 | 35 |
| Net Profit | 22 | 29 | 32 | 29 | 33 | 39 | 41 | 39 | 46 | 37 | 40 | 35 | 20 | 52 | 60 | 60 | 64 | 83 | 96 | 64 | 92 | 111 | 164 | 147 | 128 | 120 | 81 | 101 | 111 | 128 | 145 | 124 | 120 | 48 | 102 | 126 | 130 | 135 | 97 | 118 |
| EPS in ₹ | 1.10 | 1.40 | 1.58 | 1.42 | 1.60 | 1.80 | 1.88 | 1.79 | 2.09 | 1.61 | 1.76 | 1.38 | 0.81 | 2.04 | 2.37 | 2.37 | 2.52 | 3.27 | 3.77 | 2.52 | 3.63 | 4.39 | 6.60 | 5.92 | 5.15 | 4.85 | 3.26 | 4.07 | 4.48 | 5.14 | 5.85 | 5.11 | 4.94 | 1.98 | 4.22 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 |
Granules
490.85
+0.45
(0.09%)
There are new updates from the company23 hours ago
View
Market Cap
11,902.80 Cr
EPS
16.73
PE Ratio
24.83
Dividend Yield
0.31 %
Industry
Healthcare52 Week High
721.00
52 Week Low
389.35
PB Ratio
3.47
Debt to Equity
0.40
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Granules India Approves Internal Restructuring of US Subsidiaries2 days ago
Granules India's board has approved an internal restructuring plan for its US subsidiaries. The company has stated that this restructuring will not result in any changes to the ultimate ownership or the nature of its business operations in the United States.
Granules India: Board Approves US Subsidiary Restructuring Plan2 days ago
Granules India's board approved an internal restructuring plan for its US subsidiaries. Granules USA, Inc. will transfer its business and assets to Granules Pharmaceutical, Inc. The plan aims to simplify organizational structure, reduce legal entities, and improve market focus. The company also appointed PN Baskaran as President – Head of API Manufacturing and Operations, effective April 2, 2025.
Granules India Approves Internal Restructuring of US Subsidiaries2 days ago
Granules India's board has approved an internal restructuring plan for its US subsidiaries. The company emphasized that this restructuring will not result in any changes to the ultimate ownership or the nature of its business operations in the United States.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,710.40 | #1 4,10,382.25 | 35.22 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 54.16 | |
5,852.85 | 1,55,374.78 | 75.20 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 56.90 | |
1,458.60 | 1,17,798.72 | 24.00 | 26,520.70 | 14.17 | 4,155 | 47.38 | 51.80 | |
3,239.25 | 1,09,630.94 | 58.64 | 10,785.70 | 11.59 | 1,656 | 13.54 | 59.74 | |
2,449.55 | 1,01,063.17 | 49.78 | 10,615.60 | 19.57 | 1,942 | -16.38 | 59.91 | |
1,142.00 | 95,294.80 | #1 18.06 | 28,905.40 | 12.36 | 5,578 | 1.69 | 47.74 | |
2,003.00 | 91,445.15 | 32.14 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 47.45 | |
891.60 | 89,715.82 | 19.77 | 19,831.50 | 13.82 | 3,831 | 29.92 | 42.86 | |
1,161.15 | 67,439.78 | 19.21 | 29,559.20 | 17.55 | 3,169 | -10.04 | 53.81 | |
30,478.00 | 64,763.62 | 48.70 | 6,097.20 | 10.80 | 1,201 | 16.01 | 55.29 |
Growth Rate
Revenue Growth
-0.33 %
Net Income Growth
-21.54 %
Cash Flow Change
-40.52 %
ROE
-31.01 %
ROCE
-21.01 %
EBITDA Margin (Avg.)
-6.98 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,203 | 1,563 | 1,879 | 2,677 | 2,983 | 3,228 | 3,714 | 4,513 | 4,905 | 5,521 |
| Fixed Assets | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,096 |
| Current Assets | 500 | 818 | 828 | 1,187 | 1,282 | 1,629 | 1,997 | 2,505 | 2,574 | 2,905 |
| Capital Work in Progress | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 272 |
| Investments | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 22 |
| Other Assets | 524 | 856 | 859 | 1,229 | 1,332 | 1,711 | 2,123 | 2,596 | 2,733 | 3,132 |
| Total Liabilities | 1,203 | 1,563 | 1,879 | 2,677 | 2,983 | 3,228 | 3,714 | 4,513 | 4,905 | 5,521 |
| Current Liabilities | 415 | 655 | 787 | 878 | 897 | 893 | 1,173 | 1,642 | 1,814 | 2,082 |
| Non Current Liabilities | 357 | 247 | 188 | 495 | 557 | 491 | 367 | 284 | 256 | 213 |
| Total Equity | 431 | 662 | 904 | 1,304 | 1,530 | 1,844 | 2,173 | 2,587 | 2,835 | 3,226 |
| Reserve & Surplus | 411 | 613 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 3,201 |
| Share Capital | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 24 | 75 | -82 | 66 | -25 | 103 | -144 | 143 | 107 | 90 |
| Investing Activities | -146 | -162 | -326 | -462 | -270 | -160 | -277 | -379 | -192 | -358 |
| Operating Activities | 150 | 151 | 188 | -1 | 262 | 476 | 433 | 332 | 739 | 439 |
| Financing Activities | 19 | 86 | 56 | 529 | -17 | -213 | -299 | 190 | -440 | 8 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 42.04 % | 42.04 % | 42.04 % | 41.98 % | 41.98 % | 41.98 % | 41.93 % | 42.02 % | 42.02 % | 42.02 % | 42.02 % | 41.96 % | 41.96 % | 41.96 % | 38.87 % | 38.87 % | 38.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 19.57 % | 20.39 % | 19.49 % | 15.87 % |
| DIIs | 1.50 % | 2.86 % | 2.77 % | 4.34 % | 3.97 % | 3.03 % | 4.32 % | 4.23 % | 4.76 % | 5.03 % | 6.68 % | 6.85 % | 10.14 % | 10.70 % | 14.12 % | 14.86 % | 19.57 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 26.21 % | 29.74 % | 27.00 % | 24.99 % | 24.55 % | 25.26 % | 21.72 % | 21.60 % | 20.74 % | 21.13 % | 21.91 % | 21.11 % | 20.39 % | 19.38 % | 18.78 % | 18.29 % | 17.45 % |
| Others | 30.26 % | 25.36 % | 28.19 % | 28.69 % | 29.49 % | 29.73 % | 32.03 % | 32.15 % | 32.49 % | 31.82 % | 29.39 % | 30.07 % | 27.51 % | 8.39 % | 7.84 % | 8.49 % | 8.27 % |
| No of Share Holders | 0 | 1,93,871 | 2,61,165 | 2,39,520 | 2,16,385 | 2,10,785 | 2,14,539 | 2,16,055 | 2,02,329 | 1,90,894 | 2,01,054 | 2,07,055 | 1,90,691 | 1,82,142 | 1,79,870 | 2,02,198 | 1,77,554 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.9 | 1 | 1 | 1 | 1.5 | 1.5 | 1.5 | 1.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.87 | 0.87 | 0.7 | 0.33 | 0.49 | 0.52 | 0.35 | 0.31 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Closure of Trading Window
23 hours ago
23 hours agoAnnouncement under Regulation 30 (LODR)-Change in Management2 days ago
2 days agoBoard Meeting Outcome for Outcome Of The Board Meeting2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
7 days agoUpdate9 days ago
9 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Mar 03, 2025
Mar 03, 2025Update Under Regulation 30Feb 28, 2025
Feb 28, 2025Update Under Regulation 30Feb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 28, 2025
Feb 28, 2025UpdatesFeb 27, 2025
Feb 27, 2025UpdatesFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Feb 21, 2025Board Meeting Outcome for Outcome Of The Board MeetingFeb 21, 2025
Feb 21, 2025UpdateFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Transcript Of Earnings Conference Call For Q3 Of FY25Jan 30, 2025
Jan 30, 2025UpdateJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Jan 24, 2025Un-Audited Financial Results For The Quarter & Nine-Months Ended On December 31 2024Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 09, 2025
Jan 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 09, 2025
Jan 09, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024.Jan 08, 2025
Jan 08, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 17, 2024
Dec 17, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 17, 2024
Dec 17, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 10, 2024
Dec 10, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2024
Dec 09, 2024UpdateDec 04, 2024
Dec 04, 2024UpdateDec 03, 2024
Dec 03, 2024Announcement under Regulation 30 (LODR)-Change in ManagementDec 02, 2024
Dec 02, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2024
Nov 27, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2024
Nov 14, 2024Transcript Of The Earnings Conference Call For Q2 And Half Year Of FY25.Nov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 08, 2024
Nov 08, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2024
Nov 06, 2024Unaudited Financial Results For The Second Quarter And Half Year Ended On September 30, 2024.Nov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 21, 2024
Oct 21, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 18, 2024
Oct 18, 2024Board Meeting Intimation for Considering The Unaudited Consolidated And Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2024.Oct 17, 2024
Oct 17, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 14, 2024
Oct 14, 2024Closure of Trading WindowSep 27, 2024
Sep 27, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2024
Sep 24, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Sep 16, 2024
Sep 16, 2024Technical Indicators
RSI(14)
Neutral 43.48
ATR(14)
Less Volatile 18.64
STOCH(9,6)
Neutral 72.66
STOCH RSI(14)
Neutral 62.87
MACD(12,26)
Bullish 3.91
ADX(14)
Strong Trend 27.75
UO(9)
Bearish 53.04
ROC(12)
Uptrend And Accelerating 2.45
WillR(14)
Neutral -44.02
About Granules
Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
Website
Chairperson NameC Krishna Prasad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
